3 unknown, 1 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow CANbridge Life Sciences Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Velaglucerase Beta ERT in Children With Gaucher Disease Velaglucerase beta - Gaucher Disease, Gaucher Disease Type 1 | Phase 3 | Not yet recruiting | CANbridge Life Sciences Ltd. | 10 | 2026-09-16 | 2026-09-29 |
| Phase 2 Study of CAN008 in Subjects With GBM CAN008, Placebo - Newly-diagnosed Glioblastoma | Phase 2 | Unknown | CANbridge Life Sciences Ltd. | 117 | 2021-10-10 | 2022-07-12 |
| To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) CAN008 - GBM | Phase 2 | Unknown | CANbridge Life Sciences Ltd. | 60 | 2018-11-20 | 2018-11-19 |
| CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma Glioblastoma | Unknown | CANbridge Life Sciences Ltd. | 62 | 2017-11-01 | 2017-09-21 | |
| A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme CAN008 - Glioblastoma Multiforme | Phase 1 | Completed | CANbridge Life Sciences Ltd. | 10 | 2016-08-01 | 2018-11-08 |
Glioblastoma (3) · Gaucher Disease (1)
China (2) · Taiwan (1)
Jinsong Wu, MD (1) · Wenbin Li, MD, PhD (1) · Ying Xu, MD (1)